ReviewMediterranean journal of rheumatology2026
Systemic Lupus Erythematosus and the Risk of Coeliac Disease: Substantial Discrepancies Among Studies Highlight a Significant Research Gap.
Review in Mediterranean journal of rheumatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Coeliac disease (CD) is an immune-mediated disorder that affects the small intestine. There are data showing that the prevalence of the disease is higher among patients with Systemic Lupus Erythematosus (SLE) compared to the general population. This narrative review investigates the correlation between these two entities. Methods: A thorough search was conducted in "PubMed," "Scopus," "Cochrane Central Register of Controlled Trials (CENTRAL)," "clinicaltrials.gov," "gray literature" and "Google Scholar" from January 1, 1982, to July 1, 2025. A total of 2,991 articles were identified, of which 74 were reviewed in full text, and ultimately 15 were included in this review. Initially, the prevalence of biopsy verified CD among patients with SLE was examined. The prevalence of autoantibodies related to CD in patients with SLE was inspected subsequently. Results: The prevalence rate of both histologically confirmed CD and CD specific autoantibodies among patients with SLE exceeds the prevalence of CD found in the general population in most of the included studies, with noteworthy variability though. Conclusion: Based on the available data, patients with SLE appear to present greater risk of developing CD than the general population. However, the results between different studies vary significantly and routine screening for CD in patients with SLE is not currently recommended. The notable discrepancies among different studies underscore the necessity for further investigation to better understand the relationship between the two disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.